Maxim Group began coverage on shares of Rein Therapeutics (NASDAQ:RNTX – Free Report) in a research note released on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $4.00 price target on the stock.
RNTX has been the topic of several other research reports. Wall Street Zen raised shares of Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Weiss Ratings cut shares of Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Finally, HC Wainwright decreased their target price on Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Rein Therapeutics currently has an average rating of “Hold” and an average price target of $6.00.
View Our Latest Stock Analysis on Rein Therapeutics
Rein Therapeutics Stock Performance
Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.30. On average, equities analysts predict that Rein Therapeutics will post -0.53 earnings per share for the current year.
Hedge Funds Weigh In On Rein Therapeutics
A number of institutional investors have recently modified their holdings of the business. Geode Capital Management LLC bought a new position in shares of Rein Therapeutics in the 2nd quarter worth $344,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Rein Therapeutics during the 2nd quarter worth $68,000. Cable Car Capital LP purchased a new position in Rein Therapeutics in the second quarter worth $588,000. Vanguard Group Inc. grew its position in Rein Therapeutics by 32.2% in the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock worth $1,338,000 after acquiring an additional 284,300 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new position in Rein Therapeutics in the third quarter valued at $35,000. Institutional investors and hedge funds own 90.89% of the company’s stock.
Rein Therapeutics Company Profile
Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.
The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Rein Therapeutics
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
